Skip to search formSkip to main contentSkip to account menu

peginterferon beta-1a

Known as: PEG IFN-beta-1a, polyethylene glycol-interferon beta-1a, polyethylene glycol-interferon-beta-1a 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Interferon-betaPolyethylene Glycols

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
ACTRIMS 2018 - Posters.
P001 Regulator of Oligodendrocyte Maturation, Mir-219, a Potential Biomarker for MS Dr. Ilona B Bruinsma, PhD1, Dr. Marie van… 
2018
2018
Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week.
2017
2017
Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE…
BackgroundSubcutaneous peginterferon beta-1a has previously been shown to reduce the number of T2-hyperintense and gadolinium… 
2017
2017
Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models.
Because of its tumor-suppressive effect, interferon-based therapy has been used for the treatment of melanoma. However, limited… 
2015
2015
Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis in the randomized ADVANCE study
Aims To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous peginterferon beta-1a in patients with… 
2015
2015
Peginterferon Beta-1a is Effective as Early as Twelve Weeks Following Treatment Initiation in Patients With Relapsing Multiple Sclerosis (S4.001)
OBJECTIVE: To investigate the early effects of subcutaneous peginterferon beta-1a (PEG-IFN) dosed every two weeks in patients… 
Review
2014
Review
2014
Pegylated Interferons: A Nurses’ Review of a Novel Multiple Sclerosis Therapy
ABSTRACT: Most multiple sclerosis (MS) therapies are injectable drugs, and the frequency of injections has been shown to be… 
2014
2014
Peginterferon Beta-1a Reduces Relapse-Associated Costs in Patients with Relapsing-Remitting Multiple Sclerosis (P4.146)
OBJECTIVE: To estimate potential relapse-associated cost savings with investigational subcutaneous peginterferon beta-1a (PEG-IFN… 
2014
2014
Interim Analysis of 2-year Clinical Efficacy and Safety of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study (S4.005)
OBJECTIVE: To evaluate interim 2-year efficacy and safety of peginterferon beta-1a in patients with relapsing-remitting multiple… 
2014
2014
Pharmacokinetics and Pharmacodynamics of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study (P3.194)
OBJECTIVE: To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of peginterferon beta-1a in patients with relapsing… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)